Long-Term Toxicity Following 3D Conformal Radiation Therapy for Prostate Cancer From the RTOG 9406 Phase I/II Dose Escalation Study-Reference-Cited by-同舟云学术

Long-Term Toxicity Following 3D Conformal Radiation Therapy for Prostate Cancer From the RTOG 9406 Phase I/II Dose Escalation Study

Published:2010-01 Issue:1 Volume:76 Page:14-22
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Michalski Jeff M.,Bae Kyounghwa,Roach Mack,Markoe Arnold M.,Sandler Howard M.,Ryu Janice,Parliament Matthew B.,Straube William,Valicenti Richard K.,Cox James D.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference21 articles.

1. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406;Michalski;Int J Radiat Oncol Biol Phys,2000

2. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V;Michalski;Int J Radiat Oncol Biol Phys,2005

3. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV;Michalski;Int J Radiat Oncol Biol Phys,2004

4. AJCC cancer staging manual,1992

5. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy);Ryu;Int J Radiat Oncol Biol Phys,2002

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypofractionated Dose Escalation Radiotherapy for High-risk Prostate Cancer: The Survival Analysis of the Prostate Cancer Study 5, a Groupe de Radio-oncologie Génito-urinaire du Quebec–led Phase 3 Trial;European Urology;2024-09

2. Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinaire de Quebec Led Phase 3 Trial;International Journal of Radiation Oncology*Biology*Physics;2024-01

3. Differential Use of Radiotherapy Fractionation Regimens in Prostate Cancer;JAMA Network Open;2023-10-10

4. PSMA‐PET‐guided dose‐escalated volumetric arc therapy for newly diagnosed lymph node‐positive prostate cancer: 5 Year outcomes following the FROGG and EviQ node‐positive guidelines;Journal of Medical Imaging and Radiation Oncology;2023-04-26

5. Quality rectal hydrogel placement allows for gel-enabled dose-escalated EBRT (GEDE-EBRT) without rectal interference in prostate cancer;Medical Dosimetry;2023